MX2020012259A - Formas cristalinas de un inhibidor de tlr7/tlr8. - Google Patents
Formas cristalinas de un inhibidor de tlr7/tlr8.Info
- Publication number
- MX2020012259A MX2020012259A MX2020012259A MX2020012259A MX2020012259A MX 2020012259 A MX2020012259 A MX 2020012259A MX 2020012259 A MX2020012259 A MX 2020012259A MX 2020012259 A MX2020012259 A MX 2020012259A MX 2020012259 A MX2020012259 A MX 2020012259A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- pyrazolo
- methyl
- tlr7
- arthritis
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 abstract 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 abstract 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 abstract 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 abstract 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010037549 Purpura Diseases 0.000 abstract 1
- 241001672981 Purpura Species 0.000 abstract 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 abstract 1
- 201000001981 dermatomyositis Diseases 0.000 abstract 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
- 208000002557 hidradenitis Diseases 0.000 abstract 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- YPSPPJRTCRMQGD-UHFFFAOYSA-N morpholine-3-carboxamide Chemical compound NC(=O)C1COCCN1 YPSPPJRTCRMQGD-UHFFFAOYSA-N 0.000 abstract 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 208000005987 polymyositis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018087448 | 2018-05-18 | ||
| PCT/IB2019/054066 WO2019220390A1 (en) | 2018-05-18 | 2019-05-16 | Crystalline forms of a tlr7/tlr8 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012259A true MX2020012259A (es) | 2021-01-29 |
Family
ID=67145832
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012259A MX2020012259A (es) | 2018-05-18 | 2019-05-16 | Formas cristalinas de un inhibidor de tlr7/tlr8. |
| MX2023013584A MX2023013584A (es) | 2018-05-18 | 2020-11-13 | Formas cristalinas de un inhibidor de tlr7/tlr8. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013584A MX2023013584A (es) | 2018-05-18 | 2020-11-13 | Formas cristalinas de un inhibidor de tlr7/tlr8. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12084460B2 (https=) |
| EP (1) | EP3793998A1 (https=) |
| JP (2) | JP7407740B2 (https=) |
| KR (1) | KR20210013554A (https=) |
| CN (1) | CN112119078A (https=) |
| AR (1) | AR117573A1 (https=) |
| AU (1) | AU2019268583B2 (https=) |
| BR (1) | BR112020022738A2 (https=) |
| CA (1) | CA3097312A1 (https=) |
| CL (1) | CL2020002967A1 (https=) |
| MX (2) | MX2020012259A (https=) |
| TW (2) | TW202417000A (https=) |
| WO (1) | WO2019220390A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ． ホフマン－ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
| EP3802539B1 (en) | 2018-06-05 | 2023-09-20 | F. Hoffmann-La Roche AG | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease |
| EP3807270B1 (en) | 2018-06-12 | 2023-09-13 | F. Hoffmann-La Roche AG | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| CN112584903B (zh) | 2018-07-23 | 2025-12-23 | 豪夫迈·罗氏有限公司 | 用于自身免疫性疾病治疗的哌嗪化合物 |
| EP3847169A1 (en) | 2018-09-04 | 2021-07-14 | F. Hoffmann-La Roche AG | Benzothiazole compounds for the treatment of autoimmune diseases |
| EP3847173B1 (en) | 2018-09-06 | 2023-04-12 | F. Hoffmann-La Roche AG | Novel pyrazolopyridine compounds for the treatment of autoimmune disease |
| US11548884B2 (en) | 2018-09-06 | 2023-01-10 | Hoffmann-La Roche Inc. | Cyclic amidine compounds for the treatment of autoimmune disease |
| WO2021084022A1 (en) | 2019-10-31 | 2021-05-06 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| CN114728976B (zh) | 2019-11-19 | 2024-08-16 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物 |
| WO2021099406A1 (en) | 2019-11-20 | 2021-05-27 | F. Hoffmann-La Roche Ag | Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease |
| US20240317735A1 (en) | 2020-07-14 | 2024-09-26 | Hoffmann-La Roche Inc. | Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease |
| CR20230478A (es) | 2021-04-16 | 2023-11-30 | Gilead Sciences Inc | Compuestos de tienopirrol. |
| KR20240056747A (ko) | 2021-09-10 | 2024-04-30 | 길리애드 사이언시즈, 인코포레이티드 | 티에노피롤 화합물 |
| PE20250401A1 (es) | 2021-09-24 | 2025-02-11 | Hoffmann La Roche | Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades auto/inmunitarias |
| AU2023207313A1 (en) * | 2022-01-11 | 2024-06-13 | Novartis Ag | Tlr7/8-antagonist for treating sjögren's syndrome or mixed connective tissue disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2222545A1 (en) | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
| AU2006279548A1 (en) | 2005-08-16 | 2007-02-22 | Amgen, Inc. | Phosphodiesterase 10 inhibitors |
| TWI674262B (zh) | 2011-01-10 | 2019-10-11 | 美商英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
| DK2812331T3 (en) | 2012-02-08 | 2019-04-08 | Janssen Sciences Ireland Unlimited Co | PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS |
| EA029281B1 (ru) | 2013-07-30 | 2018-03-30 | Джилид Коннектикут, Инк. | Полиморф ингибиторов syk |
| EP3341375B1 (en) | 2015-08-25 | 2022-04-13 | BeiGene, Ltd. | Process for preparing parp inhibitor, crystalline forms, and uses thereof |
| GB2566245B (en) * | 2016-06-30 | 2020-09-30 | Kimberly Clark Co | Method of manufacturing a foam and fiber composite |
| HRP20220144T1 (hr) * | 2016-09-09 | 2022-04-15 | Novartis Ag | Spojevi i pripravci kao inhibitori endosomskih toll-u sličnih receptora |
-
2019
- 2019-05-16 JP JP2020564243A patent/JP7407740B2/ja active Active
- 2019-05-16 US US17/056,351 patent/US12084460B2/en active Active
- 2019-05-16 TW TW112150642A patent/TW202417000A/zh unknown
- 2019-05-16 EP EP19735624.9A patent/EP3793998A1/en active Pending
- 2019-05-16 CA CA3097312A patent/CA3097312A1/en active Pending
- 2019-05-16 KR KR1020207032942A patent/KR20210013554A/ko not_active Ceased
- 2019-05-16 BR BR112020022738-2A patent/BR112020022738A2/pt unknown
- 2019-05-16 MX MX2020012259A patent/MX2020012259A/es unknown
- 2019-05-16 AR ARP190101308A patent/AR117573A1/es not_active Application Discontinuation
- 2019-05-16 TW TW108116864A patent/TWI826446B/zh active
- 2019-05-16 WO PCT/IB2019/054066 patent/WO2019220390A1/en not_active Ceased
- 2019-05-16 CN CN201980032642.0A patent/CN112119078A/zh active Pending
- 2019-05-16 AU AU2019268583A patent/AU2019268583B2/en not_active Ceased
-
2020
- 2020-11-13 MX MX2023013584A patent/MX2023013584A/es unknown
- 2020-11-16 CL CL2020002967A patent/CL2020002967A1/es unknown
-
2023
- 2023-12-18 JP JP2023212606A patent/JP2024037930A/ja active Pending
-
2024
- 2024-08-06 US US18/795,371 patent/US20240391938A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR117573A1 (es) | 2021-08-18 |
| CL2020002967A1 (es) | 2021-04-30 |
| AU2019268583A1 (en) | 2020-10-29 |
| BR112020022738A2 (pt) | 2021-02-02 |
| US20240391938A1 (en) | 2024-11-28 |
| US12084460B2 (en) | 2024-09-10 |
| TW202015698A (zh) | 2020-05-01 |
| JP2024037930A (ja) | 2024-03-19 |
| MX2023013584A (es) | 2023-11-30 |
| US20210206783A1 (en) | 2021-07-08 |
| CN112119078A (zh) | 2020-12-22 |
| TW202417000A (zh) | 2024-05-01 |
| CA3097312A1 (en) | 2019-11-21 |
| JP7407740B2 (ja) | 2024-01-04 |
| TWI826446B (zh) | 2023-12-21 |
| EP3793998A1 (en) | 2021-03-24 |
| JP2021523918A (ja) | 2021-09-09 |
| AU2019268583B2 (en) | 2022-01-27 |
| WO2019220390A1 (en) | 2019-11-21 |
| KR20210013554A (ko) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020012259A (es) | Formas cristalinas de un inhibidor de tlr7/tlr8. | |
| EP4397371A3 (en) | Deuterated tryptamine derivatives and methods of use | |
| ME00555A (en) | Tryasolyl tropane derivatives as ccr5 modulators | |
| ZA201906209B (en) | Aryl hydrocarbon receptor antagonists and uses thereof | |
| AR065556A1 (es) | Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida | |
| NO2015020I2 (no) | Ceritinib eller et farmasøytisk akseptabelt salt derav | |
| WO2009093209A3 (ru) | 2-AЛKИЛAMИHO-3-APИЛCУЛЬФOHИЛ-ЦИKЛOAЛKAHO [e ИЛИ d] ПИPAЗOЛO [1,5-a] ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| JO2481B1 (en) | Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods | |
| WO2009093210A3 (ru) | ЗАМЕЩЕННЫЕ ЦИKЛOAЛKAHO[e ИЛИ d]ПИPAЗOЛO[l,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| DE60204674D1 (de) | Retinoid x rezeptormodulatoren | |
| CR8842A (es) | Derivados de pirido-pirimidina, su preparacion, su aplicacion en terapeutica | |
| KR960703852A (ko) | 이환상 테트라하이드로 피라졸로피리딘(bicyclic tetrahydro pyrazolopyridines) | |
| NZ598173A (en) | Pyridin-4-yl derivatives | |
| DE60023686D1 (de) | Verwendung von selektiven alpha-adrenergischen rezeptorantagonisten zur behandlung sexueller störungen | |
| MX2007000044A (es) | Compuestos, composiciones y metodos de tetrahidroquinazolin-4(3h)- ona-relacionados y tetrahidropirido [2,3-d] pirimidin-4(3h)-ona- relacionados para su uso. | |
| PE20010203A1 (es) | Derivados de 5-fenil-pirimidina como antagonistas del receptor de la neuroquinina 1 | |
| HUP9901613A2 (hu) | Szubsztituált tetraciklusos kondenzált furán-amin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| PL373460A1 (en) | Pleuromutilin derivatives as antimicrobbials | |
| AR047439A1 (es) | Antagonistas del receptor hidroisoindolina taquiquinina | |
| MY140886A (en) | Piperazinyl and diazapanyl benzamides and benzthioamides | |
| GB0314967D0 (en) | Piperazine derivatives | |
| EA202190323A1 (ru) | ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk | |
| PE20030446A1 (es) | 6-7-DIHIDRO-5H-PIRAZOLO[1,2-a]PIRAZOL-1-ONAS ESPIROCICLICAS QUE CONTROLAN CITOQUINAS INFLAMATORIAS | |
| ECSP045096A (es) | Derivados de heteroarilo como ligandos superiores para el receptor de nociceptina orl-1" | |
| UA102845C2 (en) | TETRAHYDRO-PYRAZOLO[1,5-a]PYRIDO-PYRIMIDINES AS ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THE PRODUCTION AND USE THEREOF |